Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,926,325
  • Shares Outstanding, K 40,090
  • Annual Sales, $ 276,370 K
  • Annual Income, $ -37,950 K
  • 36-Month Beta 2.33
  • Price/Sales 6.86
  • Price/Cash Flow 155.02
  • Price/Book 8.08

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.75 +9.71%
on 04/18/17
48.35 -0.72%
on 04/27/17
+0.60 (+1.27%)
since 03/28/17
3-Month
35.75 +34.27%
on 01/31/17
58.95 -18.58%
on 03/01/17
+10.75 (+28.86%)
since 01/27/17
52-Week
29.95 +60.27%
on 12/02/16
58.95 -18.58%
on 03/01/17
-7.55 (-13.59%)
since 04/28/16

Most Recent Stories

More News
Pacira Focuses on Lead Candidate Exparel's Label Expansion

We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.

HSKA : 105.94 (+0.68%)
GALE : 0.63 (+1.61%)
PCRX : 47.80 (-0.52%)
RTRX : 19.45 (-0.51%)
Dr. Kenneth Peavy is Now the First Periodontist in Winston-Salem, NC to Offer Revolutionary EXPAREL(R) Sedation Dentistry

As the first periodontist in North Carolina to offer EXPAREL(R), Dr. Kenneth Peavy now provides a solution to surgical pain relief for up to three to four days after surgery without narcotics. EXPAREL...

PCRX : 47.80 (-0.52%)
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 16th Annual Needham Healthcare Conference at 3:00 PM ET on Tuesday, April...

PCRX : 47.80 (-0.52%)
Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRX : 47.80 (-0.52%)
Research Reports Initiation on Generic Drugs Stocks -- Medicines, Ironwood Pharma, Pacira Pharma, and Supernus Pharma

This morning's research on Stock-Callers.com draws investors' attention to these four stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc....

IRWD : 16.38 (+0.18%)
MDCO : 49.04 (+0.95%)
SUPN : 32.35 (-2.56%)
PCRX : 47.80 (-0.52%)
Phase 4 Study Shows EXPAREL(R) Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty

Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedure

PCRX : 47.80 (-0.52%)
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. ET on Thursday, March 16, 2017, in...

PCRX : 47.80 (-0.52%)
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022

Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced the pricing of $300 million aggregate principal amount of convertible senior notes due 2022 (the "notes") in a private placement to qualified...

PCRX : 47.80 (-0.52%)
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes

Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2022...

PCRX : 47.80 (-0.52%)
Why Earnings Season Could Be Great for Pacira Pharmaceuticals (PCRX)

Investors are always looking for stocks that are poised to beat at earnings season and Pacira Pharmaceuticals, Inc. (PCRX) may be one such company.

PCRX : 47.80 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Support & Resistance

2nd Resistance Point 49.65
1st Resistance Point 48.85
Last Price 47.80
1st Support Level 46.75
2nd Support Level 45.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.